AU2013259486B2 - Method and compounds for inhibiting the MCM complex and their application in cancer treatment - Google Patents

Method and compounds for inhibiting the MCM complex and their application in cancer treatment Download PDF

Info

Publication number
AU2013259486B2
AU2013259486B2 AU2013259486A AU2013259486A AU2013259486B2 AU 2013259486 B2 AU2013259486 B2 AU 2013259486B2 AU 2013259486 A AU2013259486 A AU 2013259486A AU 2013259486 A AU2013259486 A AU 2013259486A AU 2013259486 B2 AU2013259486 B2 AU 2013259486B2
Authority
AU
Australia
Prior art keywords
cells
deacetyltanghinin
17beta
cancer
mcm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013259486A
Other languages
English (en)
Other versions
AU2013259486A1 (en
Inventor
Liping Bai
Zhihong Jiang
Chun LIANG
Jingrong Wang
Ziyi Wang
Zhiling Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hong Kong University of Science and Technology
Hong Kong Baptist University HKBU
Macau University of Science and Technology
Original Assignee
Hong Kong University of Science and Technology
Hong Kong Baptist University HKBU
Macau University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hong Kong University of Science and Technology, Hong Kong Baptist University HKBU, Macau University of Science and Technology filed Critical Hong Kong University of Science and Technology
Publication of AU2013259486A1 publication Critical patent/AU2013259486A1/en
Application granted granted Critical
Publication of AU2013259486B2 publication Critical patent/AU2013259486B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2013259486A 2012-05-09 2013-05-09 Method and compounds for inhibiting the MCM complex and their application in cancer treatment Active AU2013259486B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261644442P 2012-05-09 2012-05-09
US61/644,442 2012-05-09
PCT/US2013/040287 WO2013169989A1 (en) 2012-05-09 2013-05-09 Method and compounds for inhibiting the mcm complex and their application in cancer treatment

Publications (2)

Publication Number Publication Date
AU2013259486A1 AU2013259486A1 (en) 2014-12-18
AU2013259486B2 true AU2013259486B2 (en) 2019-12-12

Family

ID=49551267

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013259486A Active AU2013259486B2 (en) 2012-05-09 2013-05-09 Method and compounds for inhibiting the MCM complex and their application in cancer treatment

Country Status (9)

Country Link
US (1) US11648258B2 (enExample)
EP (2) EP4248978A3 (enExample)
JP (6) JP2015517500A (enExample)
CN (2) CN110412285B (enExample)
AU (1) AU2013259486B2 (enExample)
CA (2) CA3111702C (enExample)
ES (1) ES2949335T3 (enExample)
IN (1) IN2014MN02513A (enExample)
WO (1) WO2013169989A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019283946B2 (en) * 2017-05-19 2021-05-20 Enkang Pharmaceuticals (Guangzhou), Ltd. Crystal characteristics, preparation processes and anticancer applications of 17beta-neriifolin crystal forms
CN108948119B (zh) 2017-05-19 2023-11-21 恩康药业科技（广州）有限公司 黄夹次甙乙多晶型的晶型特征、制备方法及在抗癌上的应用
CN114177189A (zh) * 2019-03-27 2022-03-15 天津中医药大学 黄夹次乙苷作为抗肿瘤药物的应用
WO2025077888A1 (zh) * 2023-10-13 2025-04-17 恩康药业科技（广州）有限公司 一种适合外用的化合物及药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004131435A (ja) * 2002-10-11 2004-04-30 Mitsubishi Chemicals Corp 抗癌剤のスクリーニング方法及び組織の癌化の判定方法
US20090018088A1 (en) * 2006-10-27 2009-01-15 University Of Louisville Research Foundation Treating cancer with cardiac glycosides

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0592990A (ja) 1991-08-06 1993-04-16 Taisho Pharmaceut Co Ltd カルデノライド誘導体
WO2002014343A1 (en) 2000-08-17 2002-02-21 Terness, Peter Bufadienolide derivatives and use as immunosuppressive, antiinflammatory and analgesic agents
US8318922B2 (en) 2002-08-29 2012-11-27 The Hong Kong Polytechnic University Treatment and prevention of hyperproliferative conditions in humans and antisense oligonucleotide inhibition of human replication-initiation proteins
US7393950B2 (en) 2002-08-29 2008-07-01 Hong Kong University Of Science & Technology Antisense oligonucleotides targeted to human CDC45
DE10248751A1 (de) 2002-10-18 2004-05-06 Berdel, Wolfgang E., Prof. Dr.med. Dyslokalisationsmoleküle und deren Verwendung
US20070207120A1 (en) * 2004-04-14 2007-09-06 Sarah Drayton Selective Killing Of Cancer Cells By Induction Of Acetyltransferase Via Tnf-Alpha And Il-6
US20090022708A1 (en) 2004-12-22 2009-01-22 Lobie Peter E Trefoil Factors and Methods of Treating Proliferation Disorders Using Same
EP1787645A1 (en) 2005-11-18 2007-05-23 Institut Curie New method for treating cancer based on the modulation of the calcineurin and/or the calcineurin/NFAT pathway
CN101683359B (zh) * 2008-09-28 2012-05-09 上海秀新臣邦医药科技有限公司 一种治疗肿瘤的中药组合物及其制备方法
CN101726577A (zh) * 2008-10-13 2010-06-09 中山大学 通过干扰巢蛋白表达来筛选抑制肿瘤增殖和促进细胞凋亡的药物的方法
WO2010068247A1 (en) 2008-12-10 2010-06-17 Sloan-Kettering Institute For Cancer Research Cardenolides for the treatment of ocular cancer
CN102219821A (zh) 2011-05-05 2011-10-19 沈阳药科大学 一类强心苷类化合物及其抗肿瘤用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004131435A (ja) * 2002-10-11 2004-04-30 Mitsubishi Chemicals Corp 抗癌剤のスクリーニング方法及び組織の癌化の判定方法
US20090018088A1 (en) * 2006-10-27 2009-01-15 University Of Louisville Research Foundation Treating cancer with cardiac glycosides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KARIMI, S and SADR, M. "Mini-Chromosome Maintenance Protein Family: Novel Proliferative Markers - The Pathophysiologic Role and Clinical Application" In: "DNA Replication and Related Cellular Processes", 2011. ISBN: 978-9-53-307775-8 *
KIMURA, H. et al., 'Mouse MCM proteins: complex formation and transportation to the nucleus' GENES TO CELLS, 1996, Vol. 1, pages 977-993. *
SHEN, L-R et al. "Chemical Constituents of Plants from the Genus Cerbera". CHEMISTRY & BIODIVERSITY, 2007, vol.4, pages 1438-1449 *
TOYOKAWA, G et al. "Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer", MOLECULAR CANCER, 2011, vol. 10(1): page 65 *

Also Published As

Publication number Publication date
AU2013259486A1 (en) 2014-12-18
EP4248978A2 (en) 2023-09-27
CA3111702C (en) 2025-03-18
EP2846807A4 (en) 2016-07-27
CA3111702A1 (en) 2013-11-14
EP2846807B1 (en) 2023-06-07
CA2873283C (en) 2021-05-04
US20150099712A1 (en) 2015-04-09
WO2013169989A1 (en) 2013-11-14
JP2021193132A (ja) 2021-12-23
JP2025169320A (ja) 2025-11-12
EP2846807A1 (en) 2015-03-18
ES2949335T3 (es) 2023-09-27
EP4248978A3 (en) 2023-11-08
CN104736157A (zh) 2015-06-24
JP2020073544A (ja) 2020-05-14
JP2018100274A (ja) 2018-06-28
IN2014MN02513A (enExample) 2015-07-17
JP2024001049A (ja) 2024-01-09
EP2846807C0 (en) 2023-06-07
JP2015517500A (ja) 2015-06-22
CN104736157B (zh) 2019-06-11
US11648258B2 (en) 2023-05-16
CN110412285A (zh) 2019-11-05
CA2873283A1 (en) 2013-11-14
CN110412285B (zh) 2022-11-15

Similar Documents

Publication Publication Date Title
JP2025169320A (ja) Ｍｃｍ複合体の形成を阻害する方法および抗ガン化合物についてスクリーニングする方法
De et al. Plumbagin from a tropical pitcher plant (Nepenthes alata Blanco) induces apoptotic cell death via a p53-dependent pathway in MCF-7 human breast cancer cells
Kumar et al. Usnic acid induces apoptosis in human gastric cancer cells through ROS generation and DNA damage and causes up-regulation of DNA-PKcs and γ-H2A. X phosphorylation
Lin et al. Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors
Das et al. Mahanine, A dietary phytochemical, represses mammary tumor burden in rat and inhibits subtype regardless breast cancer progression through suppressing self-renewal of breast cancer stem cells
Li et al. The effect of dihydroartemisinin on the malignancy and epithelial-mesenchymal transition of gastric cancer cells
Li et al. Solamargine induces apoptosis associated with p53 transcription-dependent and transcription-independent pathways in human osteosarcoma U2OS cells
Xu et al. In vitro and in vivo antitumor effects of plant-derived miliusanes and their induction of cellular senescence
JP7537684B2 (ja) 生物活性Ｇａｎｏｄｅｒｍａ ｌｕｃｉｄｕｍ化合物および抗がん誘導体の合成；細胞の局在のためのエルゴステロールペルオキシドプローブ
Guo et al. Ginsengenin derivatives synthesized from 20 (R)-panaxotriol: Synthesis, characterization, and antitumor activity targeting HIF-1 pathway
Wang et al. Liquiritigenin inhibits the migration, invasion, and EMT of prostate cancer through activating ER stress
Han et al. A new semisynthetic 1-O-acetyl-6-O-lauroylbritannilactone induces apoptosis of human laryngocarcinoma cells through p53-dependent pathway
Liu et al. Modification of a natural diterpene and its antitumor mechanism: Promoting apoptosis, suppressing migration, and inhibiting angiogenesis
ES2250406T3 (es) Derivados de triterpenoides.
US20230293564A1 (en) Method and compounds for inhibiting the MCM complex and their application in cancer treatment
HK40100635A (en) Method and compounds for inhibiting the mcm complex and their application in cancer treatment
KR102293156B1 (ko) 간세포 암종에 대한 치료제로서의 우트트로시드(Uttroside) B 및 이의 유도체
Thuy et al. In vivo anticancer activity of maesopsin 4-O-β-glucoside isolated from leaves of Artocarpus tonkinensis a. Chev. Ex Gagnep
Le et al. Acorus gramineus extract decreases cancer stem cell properties and stimulates ROS signaling pathway in HepG2 hepatocellular carcinoma cells
HK40016841A (en) Method and compounds for inhibiting the mcm protein complex and their application in cancer treatment
HK40016841B (en) Method and compounds for inhibiting the mcm protein complex and their application in cancer treatment
Chen et al. Ovatodiolide inhibited hepatocellular carcinoma stemness through SP1/MTDH/STAT3 signaling pathway
Al-Zubaidi et al. PTU, a novel ureido-fatty acid, inhibits MDA-MB-231 cell invasion and dissemination by modulating Wnt5a secretion and cytoskeletal signaling
Niu et al. Scutebarbatine B Exerts Anti‐Breast Cancer Activity by Inducing Cell Cycle Arrest and Apoptosis Through Multiple Pathways
EP3403661B1 (en) Marine organism-derived extract, compound, and medical composition having niche formation suppressing activity of leukemic stem cells

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 10 FEB 2018 TO 10 DEC 2019 IN WHICH TO GAIN ACCEPTANCE AND PAY THE CONTINUATION FEE HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO GAIN ACCEPTANCE AND PAY THE CONTINUATION FEE HAS BEEN EXTENDED TO 10 DEC 2019

FGA Letters patent sealed or granted (standard patent)